Equities Analysts Offer Predictions for FATE FY2025 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the biopharmaceutical company will post earnings of ($1.67) per share for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Several other research analysts also recently commented on FATE. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. Finally, Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.75.

Fate Therapeutics Trading Up 1.5 %

Shares of FATE opened at $1.34 on Wednesday. The company has a market capitalization of $152.61 million, a PE ratio of -0.81 and a beta of 2.02. Fate Therapeutics has a 12 month low of $1.04 and a 12 month high of $8.83. The stock’s 50-day moving average price is $1.96 and its two-hundred day moving average price is $3.01.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.02. The business had revenue of $3.07 million for the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.

Insider Activity at Fate Therapeutics

In related news, Director Redmile Group, Llc acquired 397,964 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was purchased at an average cost of $1.68 per share, with a total value of $668,579.52. Following the acquisition, the director now owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. This trade represents a 3.19 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Fate Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in Fate Therapeutics by 18.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company’s stock worth $6,431,000 after purchasing an additional 283,080 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Fate Therapeutics in the second quarter valued at approximately $1,133,000. Deerfield Management Company L.P. Series C grew its holdings in shares of Fate Therapeutics by 62.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,555,871 shares of the biopharmaceutical company’s stock valued at $11,663,000 after acquiring an additional 1,365,463 shares in the last quarter. Barclays PLC grew its holdings in shares of Fate Therapeutics by 245.3% in the third quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company’s stock valued at $1,485,000 after acquiring an additional 301,389 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Fate Therapeutics in the second quarter valued at approximately $1,799,000. 97.54% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.